Longitudinal quality of life data can provide insights on the impact of adjuvant treatment for pancreatic cancer - Subset analysis of the ESPAC-1 data

Ross Carter, Deborah D. Stocken, Payla Ghaneh, Simon R. Bramhall, A. Oláh, Deszo Kelemen, Claudio Bassi, Helmut Friess, Christo Dervenis, Nigel Spry, Markus W. Büchler, John P. Neoptolemos

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The European Study Group for Pancreatic Cancer (ESPAC-1) study is the largest study of adjuvant treatment for pancreatic ductal adenocarcinoma to date and confirmed a survival advantage for adjuvant chemotherapy but not for chemoradiation. The importance of parallel evaluation of survival and quality of life (QoL) has been recognized as fundamental and the aim was to assess QoL and quality adjusted survival. A longitudinal QoL study on a subset of ESPAC-1 patients who prospectively completed the EORTC QLQ C-30 questionnaire during treatment and follow-up. An integrated quality-survival product method was used to adjust any treatment effect on survival by a function of measured QoL, calculated over a restricted 24-month-period (QALM-24). Three hundred and sixteen patients completed 1,201 questionnaires. There were no differences between treatment groups in dimension scores at baseline (randomization). For the chemotherapy group, the mean Quality Adjusted Life Months over 24 months (QALM-24) was 9.6 (95% CI: 8.7, 11.2) months compared with the mean QALM-24 of 8.6 (95% CI: 7.6, 10.5) months for the no chemotherapy group. For the chemoradiation group, the mean QALM-24 was 7.1 (95% CI: 6.0, 9.0) months compared with the mean QALM-24 of 8.1 (95% CI: 7.0, 10.0) months for the no chemoradiation group. The previously reported survival advantage supporting the use of adjuvant chemotherapy is maintained when adjusted using quality adjusted survival methodology. Chemotherapy provided on average an additional 1.0 quality-adjusted life months within a restricted 2-year time period from the time of resection.

Original languageEnglish
Pages (from-to)2960-2965
Number of pages6
JournalInternational Journal of Cancer
Volume124
Issue number12
DOIs
Publication statusPublished - Jun 15 2009

Fingerprint

Pancreatic Neoplasms
Quality of Life
Survival
Therapeutics
Adjuvant Chemotherapy
Drug Therapy
Random Allocation
Adenocarcinoma

Keywords

  • Chemoradiation
  • Chemotherapy
  • Pancreatic cancer
  • Quality of life

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Longitudinal quality of life data can provide insights on the impact of adjuvant treatment for pancreatic cancer - Subset analysis of the ESPAC-1 data. / Carter, Ross; Stocken, Deborah D.; Ghaneh, Payla; Bramhall, Simon R.; Oláh, A.; Kelemen, Deszo; Bassi, Claudio; Friess, Helmut; Dervenis, Christo; Spry, Nigel; Büchler, Markus W.; Neoptolemos, John P.

In: International Journal of Cancer, Vol. 124, No. 12, 15.06.2009, p. 2960-2965.

Research output: Contribution to journalArticle

Carter, R, Stocken, DD, Ghaneh, P, Bramhall, SR, Oláh, A, Kelemen, D, Bassi, C, Friess, H, Dervenis, C, Spry, N, Büchler, MW & Neoptolemos, JP 2009, 'Longitudinal quality of life data can provide insights on the impact of adjuvant treatment for pancreatic cancer - Subset analysis of the ESPAC-1 data', International Journal of Cancer, vol. 124, no. 12, pp. 2960-2965. https://doi.org/10.1002/ijc.24270
Carter, Ross ; Stocken, Deborah D. ; Ghaneh, Payla ; Bramhall, Simon R. ; Oláh, A. ; Kelemen, Deszo ; Bassi, Claudio ; Friess, Helmut ; Dervenis, Christo ; Spry, Nigel ; Büchler, Markus W. ; Neoptolemos, John P. / Longitudinal quality of life data can provide insights on the impact of adjuvant treatment for pancreatic cancer - Subset analysis of the ESPAC-1 data. In: International Journal of Cancer. 2009 ; Vol. 124, No. 12. pp. 2960-2965.
@article{472162a739584078953fdca991c4317b,
title = "Longitudinal quality of life data can provide insights on the impact of adjuvant treatment for pancreatic cancer - Subset analysis of the ESPAC-1 data",
abstract = "The European Study Group for Pancreatic Cancer (ESPAC-1) study is the largest study of adjuvant treatment for pancreatic ductal adenocarcinoma to date and confirmed a survival advantage for adjuvant chemotherapy but not for chemoradiation. The importance of parallel evaluation of survival and quality of life (QoL) has been recognized as fundamental and the aim was to assess QoL and quality adjusted survival. A longitudinal QoL study on a subset of ESPAC-1 patients who prospectively completed the EORTC QLQ C-30 questionnaire during treatment and follow-up. An integrated quality-survival product method was used to adjust any treatment effect on survival by a function of measured QoL, calculated over a restricted 24-month-period (QALM-24). Three hundred and sixteen patients completed 1,201 questionnaires. There were no differences between treatment groups in dimension scores at baseline (randomization). For the chemotherapy group, the mean Quality Adjusted Life Months over 24 months (QALM-24) was 9.6 (95{\%} CI: 8.7, 11.2) months compared with the mean QALM-24 of 8.6 (95{\%} CI: 7.6, 10.5) months for the no chemotherapy group. For the chemoradiation group, the mean QALM-24 was 7.1 (95{\%} CI: 6.0, 9.0) months compared with the mean QALM-24 of 8.1 (95{\%} CI: 7.0, 10.0) months for the no chemoradiation group. The previously reported survival advantage supporting the use of adjuvant chemotherapy is maintained when adjusted using quality adjusted survival methodology. Chemotherapy provided on average an additional 1.0 quality-adjusted life months within a restricted 2-year time period from the time of resection.",
keywords = "Chemoradiation, Chemotherapy, Pancreatic cancer, Quality of life",
author = "Ross Carter and Stocken, {Deborah D.} and Payla Ghaneh and Bramhall, {Simon R.} and A. Ol{\'a}h and Deszo Kelemen and Claudio Bassi and Helmut Friess and Christo Dervenis and Nigel Spry and B{\"u}chler, {Markus W.} and Neoptolemos, {John P.}",
year = "2009",
month = "6",
day = "15",
doi = "10.1002/ijc.24270",
language = "English",
volume = "124",
pages = "2960--2965",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - Longitudinal quality of life data can provide insights on the impact of adjuvant treatment for pancreatic cancer - Subset analysis of the ESPAC-1 data

AU - Carter, Ross

AU - Stocken, Deborah D.

AU - Ghaneh, Payla

AU - Bramhall, Simon R.

AU - Oláh, A.

AU - Kelemen, Deszo

AU - Bassi, Claudio

AU - Friess, Helmut

AU - Dervenis, Christo

AU - Spry, Nigel

AU - Büchler, Markus W.

AU - Neoptolemos, John P.

PY - 2009/6/15

Y1 - 2009/6/15

N2 - The European Study Group for Pancreatic Cancer (ESPAC-1) study is the largest study of adjuvant treatment for pancreatic ductal adenocarcinoma to date and confirmed a survival advantage for adjuvant chemotherapy but not for chemoradiation. The importance of parallel evaluation of survival and quality of life (QoL) has been recognized as fundamental and the aim was to assess QoL and quality adjusted survival. A longitudinal QoL study on a subset of ESPAC-1 patients who prospectively completed the EORTC QLQ C-30 questionnaire during treatment and follow-up. An integrated quality-survival product method was used to adjust any treatment effect on survival by a function of measured QoL, calculated over a restricted 24-month-period (QALM-24). Three hundred and sixteen patients completed 1,201 questionnaires. There were no differences between treatment groups in dimension scores at baseline (randomization). For the chemotherapy group, the mean Quality Adjusted Life Months over 24 months (QALM-24) was 9.6 (95% CI: 8.7, 11.2) months compared with the mean QALM-24 of 8.6 (95% CI: 7.6, 10.5) months for the no chemotherapy group. For the chemoradiation group, the mean QALM-24 was 7.1 (95% CI: 6.0, 9.0) months compared with the mean QALM-24 of 8.1 (95% CI: 7.0, 10.0) months for the no chemoradiation group. The previously reported survival advantage supporting the use of adjuvant chemotherapy is maintained when adjusted using quality adjusted survival methodology. Chemotherapy provided on average an additional 1.0 quality-adjusted life months within a restricted 2-year time period from the time of resection.

AB - The European Study Group for Pancreatic Cancer (ESPAC-1) study is the largest study of adjuvant treatment for pancreatic ductal adenocarcinoma to date and confirmed a survival advantage for adjuvant chemotherapy but not for chemoradiation. The importance of parallel evaluation of survival and quality of life (QoL) has been recognized as fundamental and the aim was to assess QoL and quality adjusted survival. A longitudinal QoL study on a subset of ESPAC-1 patients who prospectively completed the EORTC QLQ C-30 questionnaire during treatment and follow-up. An integrated quality-survival product method was used to adjust any treatment effect on survival by a function of measured QoL, calculated over a restricted 24-month-period (QALM-24). Three hundred and sixteen patients completed 1,201 questionnaires. There were no differences between treatment groups in dimension scores at baseline (randomization). For the chemotherapy group, the mean Quality Adjusted Life Months over 24 months (QALM-24) was 9.6 (95% CI: 8.7, 11.2) months compared with the mean QALM-24 of 8.6 (95% CI: 7.6, 10.5) months for the no chemotherapy group. For the chemoradiation group, the mean QALM-24 was 7.1 (95% CI: 6.0, 9.0) months compared with the mean QALM-24 of 8.1 (95% CI: 7.0, 10.0) months for the no chemoradiation group. The previously reported survival advantage supporting the use of adjuvant chemotherapy is maintained when adjusted using quality adjusted survival methodology. Chemotherapy provided on average an additional 1.0 quality-adjusted life months within a restricted 2-year time period from the time of resection.

KW - Chemoradiation

KW - Chemotherapy

KW - Pancreatic cancer

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=65649151336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65649151336&partnerID=8YFLogxK

U2 - 10.1002/ijc.24270

DO - 10.1002/ijc.24270

M3 - Article

C2 - 19330830

AN - SCOPUS:65649151336

VL - 124

SP - 2960

EP - 2965

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 12

ER -